DZ2002 是一种口服有效的、可逆的、低细胞毒性的 III 型 SAHH 抑制剂(Ki=17.9 nM),具有较好的免疫抑制活性,能通过逆转各种细胞类型的促纤维化表型来防止实验性皮肤纤维化的发展,并可用于狼疮综合征和系统性硬化症等自身免疫性疾病的研究。
产品编号: MS-E50342 纯度: 99.83% CAS No.: 33231-14-0 分子式: C10H13N5O3 分子量: 251.25
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
2mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

DZ2002 是一种口服有效的、可逆的、低细胞毒性的 III 型 SAHH 抑制剂(Ki=17.9 nM),具有较好的免疫抑制活性,能通过逆转各种细胞类型的促纤维化表型来防止实验性皮肤纤维化的发展,并可用于狼疮综合征和系统性硬化症等自身免疫性疾病的研究。

生物实验数据

生物活性 DZ2002 is an orally active, reversible, low-cytotoxicity type III SAHH inhibitor (Ki=17.9 nM) with favorable immunosuppressive activity that prevents the development of experimental skin fibrosis by reversing the profibrotic phenotype of various cell types, and can be used for research on autoimmune diseases such as lupus syndrome and systemic sclerosis.
体外研究
(In Vitro)

DZ2002 (0.1, 1, 10 μM; 96 h) inhibits the mixed lymphocyte reaction (MLR) response.
DZ2002 (0.1, 1, 10 μM; 24 h) inhibits IL-12 and TNF-α production from both mouse peritoneal exudate cells and humanTHP-1 Cells.
DZ2002 (0.1, 1, 10 μM; 64 h) inhibits expression of B7 (CD80/CD86) on differentiated THP-1 cells.

Cell Proliferation Assay

Cell Line: BALB/c and C57BL/6 splenocytes (Mitomycin C-pretreated; mixed lymphocyte)
Concentration: 0.1, 1, 10 µM
Incubation Time: 96 h
Result: Suppressed the MLR by 24.5, 42.3, and 46.0% at dosages of 0.1, 1, and 10 µM, respectively.

Cell Viability Assay

Cell Line: TG-stimulated mouse peritoneal macrophages and human THP-1 cells
Concentration: 0.1, 1, 10 µM
Incubation Time: 24 h
Result: Significantly blocked IL-12 p40 production from ~1800 pg/mL in untreated cells to ~850 pg/ml at 10 µM, and drastically reduced the active p70 form from ~1200 pg/mL in untreated cells to ~50 pg/mL.
Reduced TNF-α level by 45%.

Cell Viability Assay

Cell Line: THP-1 cells
Concentration: 0.1, 1, 10 µM
Incubation Time: 64 h
Result: Dramatically down-regulated CD80 and, in particular, CD86 expression in a dose-dependent manner.
体内研究
(In Vivo)

DZ2002 (2, 10, 50 mg/kg; i.p.; twice) blocks the DNFB-induced DTH response. (DNFB-induced DTH is a Th1 cell-mediated immune response, in which IL-12 is highly expressed and macrophages have been shown to play an important role).
DZ2002 (0.08, 2 mg/kg; i.p.; single daily for 7 days) significantly suppresses a delayed-type hypersensitivity reaction as well as antibody secretion.
DZ2002 (50, 100 mg/kg; p.o.; single daily for 4 weeks) exerts a potent anti-fibrotic effect on dermal fibrosis by reducing the production of collagen, facilitating its degradation and regulating expression of various soluble factors in SSc mice model.

Animal Model: Male and female BALB/c and C57BL/6 mice (6 to 8-week-old; DNFB-induced ear swelling model).
Dosage: 2, 10, 50 mg/kg
Administration: Intraperitoneal injection; twice (1 h before and 24 h after challenge)
Result: Suppressed ear swelling by 19.1, 28.7, and 33.1%, respectively and in a dose-dependent manner.
Animal Model: Male and female BALB/c and C57BL/6 mice (6 to 8-week-old; DNFB-induced ear swelling model).
Dosage: 0.08, 2 mg/kg
Administration: Intraperitoneal injection; single daily for 7 days.
Result: Inhibited hemolysis by 24.5 and 18.4% at doses of 0.08 and 2 mg/kg, respectively, thus decreasing anti-SRBC antibody production in vivo.
Animal Model: Wild-type C57BL/6 mice (8 to 12-week-old; BLM-induced mice model of SSc).
Dosage: 50, 100 mg/kg
Administration: Oral gavage; single daily for 4 weeks.
Result: Significantly decreased skin thickness and dermal thickness in BLM-induced mice.
Significantly reduced collagen accumulation and α-SMA expression in the dermis of mice and suppressed the mRNA expression of vascular endothelial growth factor (VEGF) in mice skin tissue.
Notably reduced collagen content and mRNA expression of the Col1a1 and Col1a2 while promoting that of the matrix metalloproteinase-13 (MMP-13) in the lesional skin of BLM-induced mice.
性状 固体
颜色 White to off-white

化学信息

分子量 251.25
分子式 C10H13N5O3
CAS No. 33231-14-0

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : ≥ 61 mg/mL (242.79 mM; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

* "≥" means soluble, but saturation unknown.

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.9802 mL19.9008 mL39.8016 mL99.5041 mL
5 mM0.7960 mL3.9802 mL7.9603 mL19.9008 mL
10 mM0.3980 mL1.9901 mL3.9802 mL9.9504 mL
15 mM0.2653 mL1.3267 mL2.6534 mL6.6336 mL
20 mM0.1990 mL0.9950 mL1.9901 mL4.9752 mL
25 mM0.1592 mL0.7960 mL1.5921 mL3.9802 mL
30 mM0.1327 mL0.6634 mL1.3267 mL3.3168 mL
40 mM0.0995 mL0.4975 mL0.9950 mL2.4876 mL
50 mM0.0796 mL0.3980 mL0.7960 mL1.9901 mL
60 mM0.0663 mL0.3317 mL0.6634 mL1.6584 mL
80 mM0.0498 mL0.2488 mL0.4975 mL1.2438 mL
100 mM0.0398 mL0.1990 mL0.3980 mL0.9950 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础